ACT 4 Children shared a post on LinkedIn:
“We’re excited to share an important milestone in the Burkitt Lymphoma project supported by Amgen, GFAOP – Groupe Franco Africain d’Oncologie Pédiatrique, and ACT 4 Children
Earlier this year, teams in Treichville, Abidjan completed an intensive week-long training program focused on preparing for the introduction of Rituximab into treatment protocols.
Despite logistical hurdles, Rituximab treatments safely arrived in Burkina Faso in early April and are now securely in place, paving the way for implementation.
Most importantly, the first patients have now been enrolled in Ouagadougou.
This marks a significant step forward in bringing innovative, life-saving treatment options closer to children affected by Burkitt lymphoma and reflects what is possible through collaboration, capacity building, and sustained commitment to equitable childhood cancer care.
Every milestone moves us closer to a future where a child’s chance of survival is not determined by geography.”
Other articles featuring ACT 4 Children on OncoDaily.
